Bliss GVS Pharma (506197) Q2 25/26 earnings summary

Executive summary

• Unaudited standalone and consolidated financial results for the quarter and half year ended September 30, 2025, were approved and published, with statutory auditors issuing unmodified limited review reports on both sets of results.

• Appointment of Mr. Shreekrushna Joshi as Head - Legal and Senior Management Personnel effective November 6, 2025.

Financial highlights

• Consolidated revenue from operations for Q2 FY26 was ₹24,439.85 lakh, up from ₹21,767.95 lakh in Q2 FY25; half-year revenue was ₹45,186.77 lakh, up from ₹40,132.22 lakh year-over-year.

• Consolidated net profit for Q2 FY26 was ₹2,858.86 lakh, compared to ₹2,569.25 lakh in Q2 FY25; half-year net profit was ₹7,294.99 lakh, up from ₹4,779.93 lakh year-over-year.

• Standalone net profit for Q2 FY26 was ₹2,479.19 lakh, compared to ₹1,704.40 lakh in Q2 FY25; half-year standalone net profit was ₹6,896.87 lakh, up from ₹3,646.41 lakh year-over-year.

• Basic EPS (consolidated) for the half year was ₹6.58, up from ₹4.22 year-over-year.

Outlook and guidance

• The company’s business activity continues to focus on the pharmaceutical and healthcare segment, with no change in segment reporting.